2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-12140
    Vestipitant 334476-46-9 98%
    Vestipitant (GW597599) is a neurokinin-1 receptor antagonist (pKi: 9.4, hNK1) with hypnotic effects and the ability to suppress primary insomnia. Vestipitant can effectively block substance P-mediated extracellular regulated kinase phosphorylation and relieve anxiety and possible depression induced by the agonist GR73632 (HY-P1192) in gerbils. Vestipitant can also improve functional dyspnea, anxiety, insomnia, irritable bowel disease, gastroesophageal reflux disease, tinnitus and antiemetic effects.
    Vestipitant
  • HY-12200
    GSK189254A hydrochloride 945493-87-8 98%
    GSK189254A hydrochloride is a novel, potent and selective histamine H3 receptor antagonist with pKi values of 9.59-9.90 and 8.51-9.17 for human and rat H3, respectively.
    GSK189254A hydrochloride
  • HY-12388
    N-Desmethyl clomipramine 303-48-0 98%
    Desmethylclomipramine (Norclomipramine) is a metabolite of Clomipramine (HY-B0457A) and can be used for neurological research.
    N-Desmethyl clomipramine
  • HY-12751
    Trimethobenzamide 138-56-7
    Trimethobenzamide (Ro 2-9578 free base) is a blocker of the D2 receptor. Trimethobenzamide is an antiemetic used to prevent nausea and vomiting.
    Trimethobenzamide
  • HY-13225
    Rivanicline oxalate 220662-95-3 98%
    Rivanicline oxalate (RJR-2403 oxalate; (E)-Metanicotine oxalate) is a neuronal nicotinic receptor agonist, showing high selectivity for the α4β2 subtype (Ki=26 nM); > 1,000 fold selectivity than α7 receptors(Ki= 3.
    Rivanicline oxalate
  • HY-13769
    TPT-260 769856-81-7 98%
    TPT-260 (TPU260) is a temporary product name, and its molecular weight in the free base form is 260, which is a derivative of thiophene thioamide.
    TPT-260
  • HY-14128
    NBI-34041 268545-87-5 98%
    NBI-34041 (SB-723620) is a selective and orally active nonpeptide CRF1 receptor antagonist with an IC50 of 58.9 nM and a Ki of 4.0 nM for human CRF1 receptor. NBI-34041 has no inhibitory effect on the CRF2 receptor. NBI-34041 can be used for depression and anxiety disorders research.
    NBI-34041
  • HY-14205
    NW-1772 911290-35-2 98%
    NW-1772 (methanesulfonate) (compound 22b) is a potent and selective monoamine oxidase (MAO) B inhibitor. NW-1772 has some advantages, such as rapid blood-brain barrier penetration, short-acting and reversible inhibitory activity, slight inhibition of selected cytochrome P450s, and low in vitro toxicity. NW-1772 can be used for the research of neurodegenerative diseases.
    NW-1772
  • HY-14338
    Idalopirdine 467459-31-0 98%
    Idalopirdine (Lu AE58054 ) is a potent, selective 5-HT6 receptor antagonist with a Ki value of 0.83 nM. Idalopirdine may be used in studies of Alzheimer's disease and schizophrenia, among other related disorders.
    Idalopirdine
  • HY-14353
    GSK-9772 928035-84-1 98%
    GSK-9772 is a Liver X Receptor (LXR) modulator of the N-phenyl tertiary amine class (NPTAs) with high affinity for LXR β ligand (IC50=30 nM). GSK-9772 has anti-inflammatory activity by binding to LXR, specifically by interacting with the region associated with the transcriptional repression function of the receptor, thereby inhibiting the expression of pro-inflammatory genes. GSK-9772 can be used in the study of inflammatory and neurodegenerative diseases.
    GSK-9772
  • HY-14409
    Lu AA41063 851202-49-8 98%
    Lu AA41063 is an adenosine A2A receptor antagonist that may be useful in the treatment of Parkinson's disease. Lu AA41063 has a Ki value of 5.9 nM and targets the human A2A receptor.
    Lu AA41063
  • HY-14477
    UPF-1035 370872-09-6 98%
    UPF-1035 is a selective PARP-2 inhibitor with an IC50 value of 0.15 μM. UPF-1035 increases CA1 pyramidal cell loss in hippocampal and has neuroprotective activity.
    UPF-1035
  • HY-14607
    Besipirdine hydrochloride 130953-69-4 98%
    Besipirdine (hydrochloride) is a potassium channel blocker with cholinergic and adrenergic activity. The cholinergic activity of Besipirdine (hydrochloride) involves stimulating phosphatidylinositol turnover and reducing potassium currents. The adrenergic activity of Besipirdine (hydrochloride) involves stimulating norepinephrine release, which is attributed to the inhibition of presynaptic α2-adrenergic receptors and the inhibition of norepinephrine uptake. Besipirdine (hydrochloride) may be used in research for Alzheimer's disease.
    Besipirdine hydrochloride
  • HY-14783
    Apricoxib 197904-84-0 98%
    Apricoxib (CS 706) is a selective inhibitor for cyclooxygenase-2 (COX-2). Apricoxib inhibits the production of PGE2 in cells with IC50 of 1.5 nM. Apricoxib exhibits anticancer, analgesic and anti-inflammatory activities.
    Apricoxib
  • HY-14793
    Lensiprazine 327026-93-7 98%
    Lensiprazine is a potent dopamine D2 receptor (D2R) antagonist that acts as a serotonin reuptake inhibitor. Lensiprazine can be used to study bipolar disorder and schizophrenia.
    Lensiprazine
  • HY-14843
    Imagabalin 610300-07-7 98%
    Imagabalin (PD-0332334 free base) is an active compound with activity for studying neurological diseases. The synthesis of imagabalin involves the reaction of 3-methylvaleric acid and Meldrum acid. During the synthesis of imagabalin, an acyl chloride intermediate species, 3-methylvaleryl chloride, was revealed for the first time. The synthesis of imagabalin also provided new information about the reaction mechanism, indicating that 3-methylvaleric anhydride is an important intermediate.
    Imagabalin
  • HY-14856
    Atagabalin 223445-75-8 98%
    Atagabalin (PD 0200390) is a selective GABA (gamma-aminobutyric acid) receptor agonist with antianxiety and sedative effects. Atagabalin enhances the activity of the GABA receptor by binding to the α2δ subunit of the GABA receptor, thereby increasing the GABA mediated inhibition. This enhancement results in reduced excitability of neurons, helping to reduce anxiety and improve sleep. Atagabalin can be used to study neuropsychiatric disorders, anxiety or sleep disorders.
    Atagabalin
  • HY-14895
    Fabomotizole 173352-21-1 99.96%
    Fabomotizole (CM346) is an insecticide with anxiolytic, antianxiety, and neuroprotective activities and a substrate of p-glycoprotein. Fabomotizole inhibits the ST-segment depression induced by isoproterenol in a rat model of acute subendocardial ischemia. Fabomotizole also inhibits Giardia lamblia and has the potential to inhibit giardiasis. Fabomotizole also targets Sigma1R, NRH:quinone reductase 2 (NQO2), and MAO-A to exert anxiolytic effects.
    Fabomotizole
  • HY-14958
    Pardoprunox 269718-84-5 98%
    Pardoprunox (SLV-308) is a partial dopamine D2 and D3 receptor partial agonist and a serotonin 5-HT1A receptor agonist, with pEC50s of 8, 9.2, and 6.3, respectively.
    Pardoprunox
  • HY-15238
    ST-836 1148156-63-1 98%
    ST-836 is a dopamine receptor ligand; Antiparkinsonian agent.
    ST-836
Cat. No. Product Name / Synonyms Application Reactivity